Upregulation of Bcl-2 and Its Promoter Signals in CD4+ T Cells during Neuromyelitis Optica Remission

Tao Yang1, Su Wang2, Xiao Yang3, Qi Zheng4,5, Lei Wang5, Qian Li1, Mingyan Wei1, Zongpan Du1 and Yongping Fan1*

1 Department of Traditional Chinese Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, 2 Department of Tumor Radiotherapy, Hizer Medical Center of Qingdao, Qingdao, China, 3 School of Management Science and Engineering, Shandong University of Finance and Economics, Jinan, China, 4 Department of Oncology, Guang An Men Hospital of China Academy of Chinese Medical Sciences, Beijing, China, 5 School of Traditional Chinese Medicine, Capital Medical University, Beijing, China

The homeostatic balance between production and elimination of CD4+ T cells in peripheral blood plays an important role in patients with neuromyelitis optica (NMO). The objective of the present study was to evaluate the anti-apoptosis genes Bcl-2 and its promoter signal (nuclear factor kappa-light-chain-enhancer of activated B cells, NFκB) in CD4+ T cells. Healthy subjects (HS, n = 25) and patients with multiple sclerosis (MS) (n = 25) and NMO (n = 30) in remission were consecutively enrolled in this prospective study between May and December 2015. CD4+ T cells were isolated using magnetic beads coated with anti-CD4 monoclonal antibodies, and gene expression of Bcl-2, NFκB, phosphatidylinositol-4, 5-bisphosphate 3-kinase/protein kinase B (PI3K/Akt), and MAP kinase kinase kinase 7 (MAP3K7) was measured by real-time reverse transcription-polymerase chain reaction (rt-PCR). Cytokines of tumor necrosis factor (TNF)-α and interleukin (IL)-1β were detected using human cytokine multiplex assay. Bcl-2 and NFκB gene expressions were elevated in NMO patients (1.63 ± 0.25; 2.35 ± 0.25) compared with those of HS (0.90 ± 0.11; 1.42 ± 0.22) and/or MS patients (1.03 ± 0.18; 1.55 ± 0.20) (P < 0.05). MAP3K7, but not Akt, was increased in NMO patients (1.23 ± 0.18; 1.56 ± 0.22) (P < 0.01) and was a significant factor related to elevated NFκB gene expressions (P < 0.001). On the other hand, IL-1β and TNF-α were also detected in the study and the results showed that both were elevated in NMO patients (23.84 ± 1.81; 56.40 ± 2.45) (P < 0.01; P < 0.05, respectively). We propose that MAP3K7 induced by IL-1β and TNF-α but not Akt promotes NFκB expression and, in turn, prolongs Bcl-2–mediated survival of CD4+ T cells in NMO patients.

Keywords: neuromyelitis optica, multiple sclerosis, Bcl-2, NFκB, MAP3K7
INTRODUCTION

Neuromyelitis optica (NMO) is an inflammatory disease characterized by NMO immunoglobulin IgG (NMO-IgG), which is primarily considered to be an AQP4-specific antibody in NMO serum (Wingerchuk et al., 2015). Despite that B cells and autoantibodies play decisive pathogenic roles in NMO, several lines of evidence suggest that T cells and cytokines have relevant roles in NMO (Varrin-Doyer et al., 2012; Zeka et al., 2015). Passive aquaporin (AQP) 4-IgG transfer alone does not produce central nervous system (CNS) pathology, but does promote the development of NMO-like lesions in recipient animals when CNS inflammation is induced by myelin-specific T cells (Vaknin-Dembinsky et al., 2012; Varrin-Doyer et al., 2012). This indicates that AQP4-IgG–specific CD4+ T cells participate in the genesis of NMO and that T cells appear to be equally crucial for the full development of the immunopathogenetic cascade (Vaknin-Dembinsky et al., 2012). Previous studies have identified the myelin/MOG specific T cells to be CD4+ cells in spontaneous CNS autoimmunity and NMO-like diseases (Dasgupta and Dasgupta, 2016; Klotz et al., 2016; Tostanoski et al., 2016). Once the T cell is stimulated by agents such as TNF-α and IL-1β, the phosphorylated MAP3K7 could phosphorylate IκB, which has the ability to phosphorylate NFκB (DiDonato et al., 1997). And, NFκB signals are required to promote the expression of Bcl-2. Protein kinase B (Akt) was suggested in another study to be an important driver of the glycolytic phenotype and is linked to many cellular processes, including anti-apoptosis and anti-autophagy (Majumder et al., 2004). Bcl-2 and its family members have the ability to control apoptosis and anti-apoptosis in balancing mitochondria permeability (the most common form of programmed cell death in biology and disease; Hotchkiss et al., 2009; Figure 1). In NMO and multiple sclerosis (MS) patients and their animal models, subtypes of CD4+ T cells were elevated compared to those of HS, and we found that one corollary of these events is the lack of balance between apoptosis and anti-apoptosis in CD4+ T cells (Uzawa et al., 2010; Wang et al., 2011). This indicates that the homeostatic balance between production and elimination of CD4+ T cells in peripheral blood plays a special role in NMO. Even though a number of pathological or physiological processes contributing to anti-apoptosis have been described, limited understanding of anti-apoptosis in CD4+ T cells in NMO hinders the development of an effective treatment. CD4+ T cell subpopulations accumulate in peripheral blood mononuclear cells (PBMCs) in NMO patients, implying anti-apoptosis might be involved in pathogenesis. Bcl-2, which has anti-apoptosis properties, was designed to value in this study. The objective of the current study was to analyze the anti-apoptotic factors in CD4+ T cells, such as Bcl-2 and its promoter signals, in NMO patients during clinical remission. We also evaluated the effects of cytokines on CD4+ T cell anti-apoptosis.

PATIENTS AND METHODS

Study Populations

Written informed consent was obtained from all subjects. The current study protocol was approved by the local ethics committee of Beijing Tiantan Hospital Affiliated with Capital Medical University China (No. KY2015-003-02). The study population comprised MS and NMO patients who were recruited from Beijing Tiantan Hospital (age 16–60; all patients met NMO or MS diagnosis; without other immune diseases; written informed consent was obtained) and healthy subjects (HS) (age 16–60; without immune diseases) from the general population. Infections were ruled out by full blood count in all subjects. This study was conducted between May and December 2015 on 25 HS, 30 MS patients, and 30 NMO patients. The NMO diagnosis was based on the revised diagnostic criteria (2006) for NMO (Wingerchuk et al., 2006; the 2015 diagnostic criteria had not been published when the study was carried out) and the MS diagnosis was determined according to the 2010 revised McDonald criteria (Polman et al., 2011).

CD4+ T Cells Collection

Peripheral blood were obtain at 9:00 a.m. using disposable ethylenediaminetetraacetic acid (EDTA) vacuum blood collection tubes (BD, USA), and PBMCs were collected by
centrifugation on a Ficoll-Hypaque density gradient. The purified CD4+ T cells were isolated using magnetic beads coated with anti-CD4 monoclonal antibody (Miltenyi Biotec, Germany) following the manufacturer’s instructions.

**Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)**

Total RNA was isolated from approximately 50 to 100 mg purified CD4+ T cells using Trizol. The concentration of each RNA sample was measured spectrophotometrically. The integrity of RNA samples was assessed by agarose gel electrophoresis. The cDNA was synthesized using the PrimeScript® RT reagent Kit with gDNA Eraser (1.0 μL) (TaKaRa bio, Japan). The PCR primers were designed using Primer Premier 6.0 (http://www.premierbiosoft.com/primerdesign/) based on the GenBank Accession codes and synthesized in Invitrogen (China). Quantitative measurement of mRNA was performed using the ABI Prism 7500 (Applied Biosystems, USA). These data were analyzed using the comparative $2^{-\Delta\Delta Ct}$ method (Livak and Schmittgen, 2001).

**Plasma Cytokines Levels**

After standing for 2.0 h at 4.0°C, the supernatant of blood samples was pipetted into EP tubes and stored at −80°C. Plasma IL-1β and TNF-α were measured using MILLIPLEX® MAP Human High Sensitivity Cytokine Panels (Cat. No. HCYTOMAG-60K) according to the manufacturer’s instructions.

**Statistical Analysis**

Statistical analysis was performed using GraphPad Prism version 5 (GraphPad Software, Inc., California, USA) and the data were reported as box and Whisker plots with the Whiskers representing minimum and maximum values. Multi-group comparisons of the means with one independent variable were carried out by one-way analysis of variance (ANOVA) test with post hoc contrasts by Student-Newman-Keuls test. The t-test was used to compare 2 groups. Pearson’s test was used to perform correlations. Power analysis was performed using G*Power (Version:3.1, Universität Regensburg, Berlin, German). A $P < 0.05$ was considered statistically significant.

**RESULTS**

We identified 25 HS, 25 MS patients, and 30 NMO patients according to demographic and clinical data (Tables 1, 2). NMO patients had more severe clinical neurological defects than MS patients ($P < 0.01$) (Table 1).

We initially investigated the Bcl-2 and NFκB gene expressions in the CD4+ T cells of HS, MS patients, and NMO patients. Overexpression of anti-apoptotic member Bcl-2 in NMO patients conforms to the higher NFκB expression in those patients (Figure 3A). NMO patients had higher expression of Bcl-2 gene comparing with HS ($P < 0.05$). Even though the results indicated NMO patients (mean = 1.63) had higher expression of Bcl-2 than MS patients (mean = 1.03), there were non-significant differences between the two ($P = 0.06$). The power analysis suggested this result might be caused by the limited number of recruiting members (setting parameter: $n_1 = 25$, $n_2 = 30$, results: power = 0.46; Figure 2). And, suppose power = 0.8 and 0.5 are satisfied, $n = 62$ and 31 in each group respectively. Given that NFκB signals are required to promote the expression of Bcl-2 gene, we examined NFκB gene expression (Wang et al., 2015). NMO patients had higher NFκB expression than HS and MS patients ($P < 0.05$) (Figure 3B).

Phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) and Akt genes were also tested in this study. Although PI3K and Akt enhances Bcl-2 promoter activity by phosphorylating NFκB, which is elevated in NMO patients, PI3K and Akt showed no significant increase in NMO patients ($P > 0.05$) (Figures 4A, B). Lacking differences in PI3K and Akt expressions in NMO patients, MAP kinase kinase 7 (MAP3K7), another NFκB promoter, was measured. The results showed a significant increase in the expression of MAP3K7 in NMO patients (vs. HS, $P < 0.05$; vs. MS patients, $P < 0.05$) (Figure 4C).

Given that upregulating MAP3K could promote NFκB gene expression, which, in turn, could enhance Bcl-2 gene expression, the correlations between NFκB and Bcl-2 and between MAP3K7 and NFκB were analyzed. Bcl-2 and NFκB and NFκB and MAP3K7 had significant correlations among all subjects ($P = 0.0016$, $P < 0.0001$, respectively; Figures 5A, B).

The cytokines TNF-α and IL-1β were detected in the study. NMO patients have higher TNF-α levels compared to HS ($P < 0.05$) and NMO patients, and MS patients had higher levels of IL-1β compared to HS ($P < 0.01$, $P < 0.05$, respectively; Figures 6A, B).

**DISCUSSION**

Unlike MS patients, NMO patients have a more severe CNS demyelinating syndrome characterized by bilateral simultaneous neuritis and acute myelitis which is in accordance with the Expanded Disability Status Scale we observed for these patients (O’Connor et al., 1998; Huh et al., 2014; Wingerchuk et al., 2015). Passive transfer of IgGs from NMO patients to experimental autoimmune encephalomyelitis rats reduced the expression of AQP4 in astrocytes coupling with severer clinical neurological
TABLE 2 | Details of MS and NMO patients.

| Patient No. | Age (year)/gender | Disease dur (month) | Dur to the last relapse | EDSS | No. of relapse |
|-------------|-------------------|---------------------|------------------------|------|---------------|
| MS-01       | 26/M              | 23                  | 25                     | 2.5  | 3             |
| MS-02       | 53/M              | 51                  | 20                     | 2.5  | 3             |
| MS-03       | 45/F              | 40                  | 57                     | 0    | 3             |
| MS-04       | 33/F              | 30                  | 33                     | 1.5  | 3             |
| MS-05       | 39/F              | 38                  | 7                      | 3    | 2             |
| MS-06       | 32/M              | 27                  | 59                     | 0    | 3             |
| MS-07       | 48/F              | 42                  | 68                     | 2.5  | 2             |
| MS-08       | 18/F              | 14                  | 44                     | 3.5  | 2             |
| MS-09       | 26/F              | 24                  | 18                     | 0    | 3             |
| MS-10       | 49/F              | 45                  | 48                     | 2    | 2             |
| MS-11       | 45/F              | 40                  | 57                     | 0    | 3             |
| MS-12       | 33/F              | 30                  | 33                     | 1.5  | 3             |

(Continued)
Yang et al. Upregulation of Bcl-2 in NMO

**FIGURE 2** | Power analysis of Bcl-2 gene expressions between MS and NMO patients. Setting parameter: \( n_1 = 25, n_2 = 30 \), results: power = 0.46. \( n_1 \): number of MS patients; \( n_2 \): number of NMO patients.

**FIGURE 3** | Bcl-2 and NF\(\kappa\)B genes expressions in CD4\(^+\) cells with HS, MS and NMO patients. (A) Comparison of Bcl-2 mRNA expression in CD4\(^+\) cells with HS, MS and NMO patients. (B) Comparison of NF\(\kappa\)B mRNA expression in CD4\(^+\) cells with HS, MS and NMO patients. HS = healthy subjects, MS = multiple sclerosis, NMO = neuromyelitis optica. * \( P < 0.05 \).

**FIGURE 4** | PI3K/Akt and MAP3K7 genes expressions in CD4\(^+\) cells with HS, MS and NMO patients. (A) Comparison of PI3K mRNA expression in CD4\(^+\) cells with HS, MS and NMO patients. (B) Comparison of Akt mRNA expression in CD4\(^+\) cells with HS, MS and NMO patients. (C) Comparison of MAP3K7 mRNA expression in CD4\(^+\) cells with HS, MS and NMO patients. HS = healthy subjects, MS = multiple sclerosis, NMO = neuromyelitis optica. ** \( P < 0.01 \).

expression in all test subjects (\( P = 0.0016 \)). This illumined NF\(\kappa\)B1 pathway has an important role in increasing Bcl-2 gene expression, in turn, to prolong the CD4\(^+\) T cells that might participate in pathogenesis in NMO patients.

Other works have shown that activated PI3K and MAP3K7 results in phosphorylating Akt, which, in turn, upregulates Bcl-2 by enhancing Bcl-2 promoter activity (Pugazhenthi et al., 2000).

The current study showed that the PI3K/Akt pathway had not changed in the NMO patients compared to that in MS patients and HS, which indicated that the PI3K/Akt pathway might not play a role in NMO pathogenesis (\( P > 0.05 \)). Meanwhile, MAP3K7 gene expression increased in NMO patients compared to that in HS and MS patients (\( P < 0.01 \)). To analyze whether the expression of NF\(\kappa\)B1 is associated with the conversion of
MAP3K7, the correlation among them was tested. The results showed that MAP3K7 is strongly correlated with NFκB1 \((P < 0.0001)\). This indicated that MAP3K7 has a decisive role in upregulating NFκB1 rather than PI3K/Akt in NMO patients.

Usually, NFκB1 is sequestered in the cytoplasm of resting cells by association with IκB family proteins (Karin and Ben-Neriah, 2000). Once the cell is stimulated by agents such as TNF-α and IL-1β, NFκB1 is activated through MAP3K7 phosphorylation (DiDonato et al., 1997). TNF-α and IL-1β have the ability to transmit survival signals as Bcl-2 by activating MAP3K7/NFκB1 transcription factors (Hagman et al., 2015). In this study, both were evaluated in NMO patients (vs. HS, \(P < 0.001\)) and MS patients (vs. HS, \(P < 0.05\)). These factors, such as Bcl-2, NFκB, MAP3K7, TNF-α, and IL-1β, somewhat inhibit apoptosis of CD4+ T cells, which might then interact with B cells and afford an opportunity to clinically relapse in NMO patients.

Collectively, this study indicated that MAP3K7 expression is stimulated by TNF-α and IL-1β and, in turn, activates NFκB1, which has the ability to prolong Bcl-2-mediated CD4+ T cell survival in NMO patients. The aberrant longevity of CD4+ T cells can lead to pathological immune cell accumulation in NMO patients, which augments the risk of NMO relapse. These results might help identify clinical applications for enhancing the treatment of NMO; however, the study was not restricted to subgroups of CD4+ T cells and, thus, we need to test which kinds of CD4+ T cells have aberrant Bcl-2 and its promotor expressions in further studies, which might explain why MS patients have elevated subtypes of CD4+ T cells but with relatively regular Bcl-2 expression.

**AUTHOR CONTRIBUTIONS**

TY drafted this manuscript. TY, SW, and LW performed the MILLIPLEX® MAP Human High Sensitivity Cytokine/Chemokine Panels tests, performed the real-time rtPCR, and participated in collecting samples. LW, XY, QZ, QL, MW, and ZD performed the statistical analysis and evaluated the EDSS scores of patients. TY, SW, and YF participated in the design and coordination of the study. TY conceived of the study and participated in its design. LW revised the manuscript. All authors read and approved the final manuscript.
ACKNOWLEDGMENTS

YF and LW were responsible for accessing the following research funds: National Natural Science Foundation of China (CN) (81072765, 81173237, 81473640), the Program of Changcheng Scholars for the Importation and Development of High-Caliber Talents Project of Beijing Municipal Institutions (CIT&TD20140329), and the Beijing Natural Science Foundation (7142053).

REFERENCES

Bennett, J. L., Lam, C., Kalluri, S. R., Saikali, P., Bautista, K., Dupree, C., et al. (2009). Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 66, 617–629. doi: 10.1002/ana.21802
Bradl, M., Musi, T., Takahashi, T., Watanabe, M., Mader, S., Reindl, M., et al. (2009). Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 66, 630–643. doi: 10.1002/ana.21837
Chihara, N., Aranami, T., Sato, W., Miyakai, Y., Miyake, S., Okamoto, T., et al. (2011). Interleukin 6 signaling promotes anti-aquaporin 4 autotubbody production from plasmablasts in neuromyelitis optica. Proc. Natl. Acad. Sci. U.S.A. 108, 3701–3706. doi: 10.1073/pnas.1017385108
Das Gupta, S., and Das Gupta, S. (2016). Antigen presentation for priming T cells in central system. Int. J. Biochem. Cell Biol. 82, 41–48. doi: 10.1016/j.biocel.2016.11.015
DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., and Karin, M. (1997). A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388, 548–554. doi: 10.1038/41493
Hageman, S., Kolasa, M., Basnyat, P., Helmingen, M., Kahonen, M.,Dstaidar, P., et al. (2015). Analysis of apoptosis-related genes in patients with clinically isolated syndrome and their association with conversion to multiple sclerosis. J. Neuroimmunol. 280, 43–48. doi: 10.1016/j.jneuroim.2015.02.006
Hotchkiss, R. S., Strasser, A., McDunn, J. E., and Swanson, P. E. (2009). Cell death. Annu. Rev. Immunol. 17, 613–666. doi: 10.1146/annurev.immunol.17.092306.170109
Huh, S. Y., Kim, S. H., Hyun, J. W., Joung, A. R., Park, M. S., Kim, B. J., et al. (2014). Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 71, 1372–1378. doi: 10.1001/jamaneurol.2014.2057
Karin, M., and Ben-Neriah, Y. (2000). Phosphorylation meets ubiquitination: an FRliexion-6. Multi. Scir. 16, 1443–1452. doi: 10.1152/jsi.2012.60.3.24
Vaknin-Dembinsky, A., Brill, L., Kassis, I., Petrov, T., Ovadia, H., Ben-Hur, T., et al. (2012). T-cell reactivity against AQP4 in neuromyelitis optica. Neurology 79, 945–946. doi: 10.1212/WNL.0b013e3182666cad
Varrin-Doyer, M., Spencer, C. M., Schulze-Topphoff, U., Nelson, P. A., Stroud, R. M., Cree, B. A., et al. (2012). Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Cleotroabid ABC transporter. Ann. Neurol. 72, 53–64. doi: 10.1002/ana.23651
Verma, N., and Manna, S. K. (2016). Advanced glycation end products (AGE) potently induce autophagy through activation of RAF protein kinase and nuclear factor κB (NF-κB). J. Biol. Chem. 291, 1481–1491. doi: 10.1074/jbc.M115.667576
Wang, H. H., Dai, Y. Q., Qu, W., Lu, Z. Q., Peng, F. H., Wang, Y. G., et al. (2011). Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J. Clin. Neurosci. 18, 1313–1317. doi: 10.1016/j.jocn.2011.01.031
Wang, Y., Wang, R., Wang, Y., Peng, R., Wu, Y., and Yuan, Y. (2015). Gingko biloba extract mitigates liver fibrosis and apoptosis by regulating p38 MAPK, NF-κB/JkBa, and Bcl-2/Bax signaling. Drug Des. Devel. Ther. 9, 6303–6317. doi: 10.2147/DDDT.S93732
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., et al. (2015). International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85, 177–189. doi: 10.1212/WNL.0000000000001729
Wingerchuk, D. M., Lennon, V. A., Pittcock, S. L., Lucchetti, C. F., and Weinzshenker, B. G. (2006). Revised diagnostic criteria for neuromyelitis optica. Neurology 66, 1485–1489. doi: 10.1212/01.wnl.0000216139.44259.74
Zeka, B., Hastermann, M., Hochmeister, S., Kögl, N., Kaufmann, N., Schanda, K., et al. (2015). Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS. Acta. Neuropathol. 130, 783–798. doi: 10.1007/s00401-015-1501-5

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Yang, Wang, Yang, Zheng, Wang, Li, Wei, Du and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.